Three years of fruitful collaboration: Nuvisan Berlin and Bayer Pharmaceuticals

Nuvisan has been collaborating strategically with Bayer Pharmaceuticals in the field of drug discovery for three years now. At the end of May 2023, Bayer and Nuvisan held a scientific forum to celebrate the achievements, discuss future scientific opportunities, and strengthen strategic partnership and interactive knowledge exchange.

Merging Nuvisan therapeutic and drug discovery excellence with Bayer’s broad expertise, has yielded significant progress in drug discovery and achievement of numerous milestones. Nuvisan has supported nearly 300 individual projects across Bayer's pipeline, spanning the full value chain of early drug discovery from idea generation to identifying preclinical candidates since the collaboration began. The development of gene editing and cell therapy platforms as well as next-generation sequencing capabilities are examples of these accomplishments.

One of the projects through the collaboration is the discovery of a highly selective, orally available inhibitor of a diacylglycerol kinase which shows a unique binding mode and good DMPK profile for cancer immuno-therapy. The result was presented at the American Association for Cancer Research 2023: https://aacrjournals.org/cancerres/article/83/7_Supplement/ND04/727035/Abstract-ND04- BAY-2965501-A-highly-selective-DGK

‘’The spirit of collaboration between researchers at Nuvisan and Bayer is impressive’’, said Joerg Fanghaenel, former Managing Director and Chief Operating Officer at Berlin. ‘’Building on the success of the first three years, we look into the future of our collaboration with great optimism’’. Completing three years of collaboration, we value strategic partnerships for scientific advancement, with the goal of pushing scientific boundaries and impacting patients’ lives. Our collaboration will continue to progress.